Companies / Roivant Sciences Ltd.
Roivant Sciences Ltd.
Nasdaq: ROIVCIK 1635088LONDON
Financials · FY2025
Ownership
722.3M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 6.92% | 50,014,504 |
| 10%+ / strategic | 9.11% | 65,779,464 |
| Institutions | 63.45% | 458,323,126 |
| Public float | 20.52% | 148,205,921 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 12
View all →| Insider | % of shares | Shares |
|---|---|---|
Sukhatme MayukhPresident & CIO · Director | 2.61% | 18,836,547 |
Manchester Keith SDirector | 2.14% | 15,437,569 |
Gold Daniel AllenFormerDirector | 2.09% | 15,127,329 |
Torti FrankPresident and Vant Chair | 1.90% | 13,736,547 |
| 1.90% | 13,689,166 | |
Venker EricCEOPresident & Immunovant CEO | 0.23% | 1,647,546 |
| 0.03% | 236,867 | |
Oren IlanDirector | 0.02% | 119,428 |
Momtazee James CFormerDirector | 0.02% | 109,405 |
Humes JenniferFormerChief Accounting Officer | 0.01% | 97,729 |
Institutional holders 415
View all →| Holder | Value | % of shares |
|---|---|---|
| $1.71B | 6.68% | |
| $1.43B | 9.11% | |
| $1.27B | 8.08% | |
| $912.68M | 5.82% | |
| $696.97M | 3.48% | |
| $629.80M | 2.46% | |
| $399.08M | 2.55% | |
| $356.18M | 2.27% | |
| $354.40M | 1.77% | |
| $282.11M | 1.41% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $250.05M | +7.1M +17.16% | 48,236,091 6.68% of shares | high |
| Q1 2026 as of | AQR Capital Management, LLC 13F manager | Add | — | $137.70M | +5.1M +575.19% | 5,946,858 0.82% of shares | high |
| Q1 2026 as of | Norges Bank 13F manager | Exit | — | $-112.75M | -5.2M -100.00% | — | high |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Add | — | $58.62M | +2.1M +19.82% | 12,794,097 1.77% of shares | high |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | — | $56.21M | +2.0M +24.88% | 10,182,477 1.41% of shares | high |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Exit | — | $-47.54M | -2.2M -100.00% | — | medium |
| Q1 2026 as of | QVT Financial LP 13F manager | Trim | — | $-33.95M | -1.2M -4.65% | 25,161,237 3.48% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | — | $-33.57M | -1.2M -35.04% | 2,246,943 0.31% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Ramaswamy Vivek | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| Morgan Stanley | Passive13G/A | — |
| Sb Investment Advisers (Uk) Ltd | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ROIV | — | G76279101 |